Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury

J Pediatr Endocrinol Metab. 2006 Feb;19(2):129-34. doi: 10.1515/jpem.2006.19.2.129.

Abstract

Unrelenting weight gain, morbid obesity and disturbance of the sleep-wake cycle are well-recognized sequelae of hypothalamic injury. These health problems and their risk of significant associated co-morbidity drive the search for potential treatment modalities.

Objective: To report effects on weight change and wakefulness in a cohort of 12 patients with structural hypothalamic lesions treated with low-dose dexamphetamine.

Method: Retrospective review of case notes.

Results: Twelve patients received dexamphetamine 5 mg twice daily (median duration 13 months in males, 15 months in females). Ten of 12 patients experienced either stabilisation of weight or weight loss on treatment (median loss -0.7 SDS in males, -0.44 SDS in females). Eleven patients reported improvement in daytime wakefulness and/or concentration and exercise tolerance.

Conclusion: Low-dose dexamphetamine therapy has a positive impact on inexorable weight gain and daytime somnolence following hypothalamic injury.

MeSH terms

  • Adolescent
  • Central Nervous System Stimulants / therapeutic use*
  • Child
  • Child, Preschool
  • Craniopharyngioma / complications
  • Craniopharyngioma / surgery
  • Dextroamphetamine / therapeutic use*
  • Disorders of Excessive Somnolence / drug therapy*
  • Disorders of Excessive Somnolence / etiology
  • Female
  • Humans
  • Hypothalamic Diseases / complications*
  • Hypothalamic Diseases / drug therapy
  • Hypothalamus / drug effects*
  • Hypothalamus / physiopathology
  • Male
  • Obesity / drug therapy*
  • Obesity / etiology*
  • Obesity / prevention & control
  • Pituitary Neoplasms / complications
  • Pituitary Neoplasms / surgery
  • Retrospective Studies
  • Weight Gain / drug effects

Substances

  • Central Nervous System Stimulants
  • Dextroamphetamine